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Coronavirus disease 2019 (COVID-19), 
caused by severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), has turned 
into a global pandemic. No agent has 
proved effective against coronavirus 
infections, and the development of novel 
therapeutics is critical to solve this public 
health crisis. Granulocyte–macrophage 
colony-stimulating factor (GM-CSF), an 
important myelopoietic growth factor and 
pro-inflammatory cytokine, has attracted 
great interest as a therapeutic target in 
COVID-19. Increased percentages of 
GM-CSF-expressing leukocytes have 
been found in the blood of patients with 
COVID-19 (ref.1), and inhibition of GM-CSF 
has shown benefit in animal studies of 
many hyperinflammatory conditions2,3 
that are thought to be pathologically 
similar to late stages of COVID-19. As of 
28 May 2020, six companies had initiated 
randomized controlled clinical trials and 
open-label studies and/or expanded access/
compassionate use programmes assessing 
the use of monoclonal antibodies (mAbs) to 
GM-CSF or GM-CSF receptor (GM-CSFR) 
to treat various stages of COVID-19 
(refs4–9). Conversely, GM-CSF plays an 
important role in alveolar macrophage 
homeostasis and lung pathogen clearance2, 
and investigator-initiated trials are studying 
the administration of recombinant human 
GM-CSF (sargramostim) in patients with 
respiratory failure due to COVID-19. 
mutations that ablate GM-CSFR function) 
causes pulmonary alveolar proteinosis 
(PAP), a life-threatening interstitial lung 
disease in which dysfunctional alveolar 
macrophages cannot clear surfactant16. 
Patients with PAP have increased 
susceptibility to opportunistic infections 
due to defective antimicrobial function 
of alveolar macrophages and basal 
circulating neutrophils, caused by impaired 
GM-CSF signalling16,17. In mice, GM-CSF 
has been reported to be required for the 
steady-state maintenance of non-lymphoid 
tissue-resident CD103+ dendritic cells across 
multiple tissues, and this population of cells 
was shown to be critically important for 
the initiation of CD8+ T cell responses in the 
lung18,19. GM-CSF thus serves a crucial role 
in normal lung health and can be important 
for host defence.
Role in inflammation. During inflammation, 
GM-CSF can be secreted by several 
different cell types, including epithelial 
cells and leukocytes, and is a critically 
important cytokine that can drive both 
innate and adaptive immune responses 
(fig. 1). GM-CSFR is mainly expressed 
on myeloid cells, generally restricting the 
direct-acting function of GM-CSF to cells 
of this lineage. GM-CSF broadly serves 
two important roles during the immune 
response: it polarizes mature myeloid 
cells into a pro-inflammatory phenotype 
(paracrine/autocrine function), and it 
governs ‘emergency myelopoiesis’, expanding 
and mobilizing progenitor myeloid cells to 
sites of inflammation (endocrine function)2. 
GM-CSF-activated myeloid cells can secrete 
reactive oxygen species and express elevated 
levels of pro-inflammatory cytokines 
(such as IL-1, IL-6 and tumour necrosis 
factor (TNF)) and a variety of chemokines 
(such as CCL2, IL-8 and CCL17, which 
can attract monocytes, neutrophils and 
lymphocytes, respectively)2. GM-CSF can 
also enhance the ability of dendritic cells 
to prime T cells during antigen-specific 
immune responses14,18. A distinct subset of 
CD4+ T helper cells (TH cells) that produce 
primarily GM-CSF has been identified20–23. 
These T cells can heighten the immune 
response by activating pro-inflammatory 
myeloid cells and recruiting them to 
sites of inflammation20–22. Thus, it has 
This Perspective provides a brief overview 
of the pleiotropic biology of GM-CSF and 
examines the preclinical and clinical studies 
supporting the use of both sargramostim 
and GM-CSF-targeting mAbs in COVID-19.
GM-CSF overview
Role in homeostasis. Macrophage 
colony-stimulating factor (M-CSF), 
granulocyte colony-stimulating factor 
(G-CSF) and GM-CSF are implicated in 
myelopoiesis, the production of monocytes, 
macrophages, dendritic cells and 
granulocytes (neutrophils, eosinophils 
and basophils) from progenitor cells. 
M-CSF and G-CSF appear to be involved 
in steady-state myelopoiesis, given that null 
mutants of the encoding genes in mice cause 
severe phenotypes (for example, skeletal 
and sensory defects and neutropenia)10–12. 
By contrast, GM-CSF is barely detectable 
in the blood of healthy individuals and is 
thought to serve less of a role in homeostatic 
myelopoiesis, as evidenced by the fact that 
GM-CSF-deficient mice have a virtually 
normal lifespan and have less dramatic 
alterations in the basal myeloid system13,14.
Importantly, however, GM-CSF is 
known to be a critical homeostatic factor 
in lung alveoli, where it is produced at low 
levels for the development and long-term 
maintenance of alveolar macrophages15,16. 
Severe deficiency of GM-CSF (for example, 
due to autoantibodies to GM-CSF or 
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been proposed that GM-CSF serves as a 
primary communication conduit between 
inflammatory lymphoid and myeloid cells14.
Role in disease. The aberrant expression 
of GM-CSF is known to drive excessive 
inflammation, pain, chemotaxis and tissue 
damage and to enhance the production of 
other pathogenic cytokines2,3. Given the 
proposed role of GM-CSF at the interface 
of lymphoid and myeloid cells, it has 
been postulated that a ‘GM-CSF network’ 
promotes disease by driving inflammatory 
responses to become persistent or 
hyperactive2. This network is defined as 
a positive-feedback loop involving the 
interdependent secretion of GM-CSF and 
pro-inflammatory cytokines/chemokines 
across monocytes/macrophages, TH cells 
and neighbouring cell populations. The 
cytokines most prominently implicated 
in this network are IL-1, IL-6 and TNF2, 
which have been targeted successfully in 
various inflammatory diseases and have 
now been suggested as potential targets in 
COVID-19 (refs24,25).
GM-CSF has been shown to be 
upregulated either systemically and/or in the 
diseased tissues of patients with autoimmune 
conditions (such as rheumatoid arthritis)2,26 
as well as in conditions that show similarities 
to late-stage COVID-19, including severe 
acute respiratory syndrome (SARS)27, acute 
respiratory distress syndrome (ARDS)28, 
cytokine release syndrome (CRS)29, 
haemophagocytic lymphohistiocytosis 
(HLH)30, hyperinflammation associated 
with graft-versus-host disease (GvHD)31 
and other inflammatory diseases of the 
lung32, heart33–35 and nervous system21,23,36,37. 
GM-CSF-producing TH cells have been 
identified as being involved in the 
pathogenesis of various immunological 
disorders (for example, rheumatoid 
arthritis26, multiple sclerosis21,22 and sepsis38), 
reminiscent of the pathogenic TH17 
pathway known to drive disease pathology 
in multiple autoimmune contexts (for 
example, psoriasis)39. GM-CSF inhibition 
via neutralizing antibodies has shown 
beneficial effects in a diverse range of 
preclinical models, including those of many 
of the aforementioned diseases3. In humans, 
treatment with GM-CSF-targeting mAbs 
has demonstrated efficacy across multiple 
phase II clinical trials for rheumatoid 
arthritis, with some potential advantages 
(for example, fewer off-target effects and 
decreased infection susceptibility) over 
standard-of-care therapeutics, such as 
disease-modifying antirheumatic drugs, 
TNF-targeting agents and Janus kinase 
inhibitors2,40 (Table 1).
GM-CSF-based therapies in COVID-19
COVID-19 clinical course and 
immunopathogenesis. Although most 
infections are mild, ~20% of patients 
with COVID-19 experience severe viral 
pneumonia that can progress to ARDS and 
death41. On the basis of emerging data, as 














































Fig. 1 | GM-CSF and inflammation. The immune response, including gran-
ulocyte–macrophage colony-stimulating factor (GM-CSF) upregulation, 
can be triggered when an antigen induces a ‘danger’ signal from a host cell. 
During this response, GM-CSF can act locally in inflamed tissue to induce 
the survival, proliferation and/or differentiation of myeloid cells, such as 
monocytes/macrophages and neutrophils. More specifically, GM-CSF 
can potentially do the following: activate mature myeloid cells to a 
pro-inflammatory phenotype with enhanced cytokine (for example, IL-1, 
IL-6 and tumour necrosis factor (TNF)) and chemokine (for example, CCL2, 
IL-8 and CCL17) secretory capacity; recruit immature myeloid cells from 
the circulation and aid in their terminal differentiation; and develop/stim-
ulate dendritic cells to prime the adaptive immune response. Activated 
lymphocytes (for example, GM-CSF-producing T helper cells) can migrate 
into diseased tissue and the circulation, serving as a source of GM-CSF, 
thereby aiding in the recruitment and activation of new myeloid cells. 
GM-CSF levels can also be elevated systemically to induce ‘emergency 
myelopoiesis’, expanding and mobilizing immature myeloid/progenitor 
haematopoietic cells in the circulation and bone marrow. These 
GM-CSF-dependent responses thus heighten the inflammatory response 
in inflamed or diseased tissue. The broad range of immunological 
activities of GM-CSF can form part of positive-feedback loops/networks 
that can initiate and maintain disease-causing hyperactive or chronic 
immune responses. GM-CSF has also been shown to enhance antimicrobial 
host defence and lung barrier repair (not shown). Blue arrows mean 
‘secretes’, black arrows mean ‘acts on’, dotted arrows indicate movement 
or differentiation and ‘host cell’ refers to various haematopoietic and 
non-hematopoietic cell types. SARS-CoV-2, severe acute respiratory 
syndrome coronavirus 2.
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epidemics42, a three-phase clinical staging 
model has been proposed for COVID-19: 
(1) fever, cough and other relatively mild 
symptoms accompanying an increase 
in viral load; (2) severe pneumonia that 
persists, despite a decline in viral load, 
due to a hyperactive immune response; 
and (3) continuation of significant 
immune dysregulation resulting in 
pulmonary destruction, cardiac instability, 
multiorgan failure and death43. It has 
become increasingly well appreciated that 
the characteristic hyperactive immune 
response driving COVID-19 progression 
consists of a ‘cytokine storm’, overwhelming 
infiltration of inflammatory myeloid cells 
into the lungs (particularly monocytes, 
macrophages and neutrophils), and 
even a disease phenotype resembling 
secondary HLH (often referred to as 
‘macrophage activation syndrome’)25,43–47. 
A subset of patients also experience acute 
myocardial injury and/or neuropsychiatric 
symptoms, which are associated with poor 
outcomes and may be caused by systemic 
inflammation48,49. Therapies aimed at 
increasing viral clearance, strengthening 
lung tissue and/or reducing the excessive 
host immune response may be able to 
reduce the morbidity and mortality 
associated with COVID-19.
Rationale for administering GM-CSF in 
COVID-19. Recombinant human GM-CSF 
(sargramostim) is FDA-approved for 
multiple indications, and its administration 
may provide several benefits to patients 
with COVID-19. As mentioned already, 
GM-CSF is required to maintain pulmonary 
function and lung sentinel cell-mediated 
immunity16,50. Overexpression of GM-CSF 
in mice prevented hyperoxia-induced lung 
injury by strengthening the resistance 
of alveolar wall cells to apoptosis and 
protecting against secondary bacterial 
infection51,52. Early elevated expression 
of GM-CSF in bronchoalveolar lavage 
fluid (BALF) of patients with acute 
lung injury and ARDS correlated with 
increased survival, potentially owing 
to the enhanced survival of alveolar 
macrophages53. On the basis of these data, 
a randomized controlled clinical trial was 
conducted to study the use of intravenously 
administered recombinant human GM-CSF 
in patients with acute lung injury or ARDS54. 
This trial failed to demonstrate reduction 
of ventilator-free days or mortality over the 
28-day observation period. However, 
the study was underpowered owing to a 
slow recruitment pace (N = 130 of planned 
200 participants)54, and it has been 
hypothesized that local delivery of high 
Table 1 | History and current status of GM-CSF-based therapies undergoing assessment in patients with COVID-19
Company Drug Completed studiesa Other indicationsa Status in COVID-19a
GlaxoSmithKline Otilimab 
(anti-GM-CSF)
Phase I or II RA (×4)
Phase Ib MS
Phase IIa hand OA
Phase III RA (ongoing, ×4) RCT (2 arms, N = 800, NCT04376684)
Roivant Gimsilumab 
(anti-GM-CSF)
Phase I HVs + RA
Phase I HVs






Phase I/II CAR T cell-related CRS/NT 
(ongoing)
Phase II CMML (planned)
Phase II/III GvHD-related CRS (planned)
Phase III eosinophilic asthma (planned)
RCT (2 arms, N = 238, NCT04351152)
Expanded access
I-Mab TJM2 (anti-GM-CSF) Phase I HVs Phase Ib RA (ongoing)
Phase II CAR T cell-related CRS/NT 
(planned)





Phase II RA (×3)
Phase II RA OLE
Phase II GCA (ongoing)
Phase II CAR T cell-related CRS/NT 
(planned)
RCT (2 arms, N = 60, NCT04399980)








Phase II axial SpA






for use in multiple 
indications
Phase I PD (ongoing)
Phase II post-transplant recovery (ongoing)
Phase II/III melanoma (ongoing)
Phase II biliary cancer (ongoing)
RCT (2 arms, N = 30, NCT04400929)
RCT (open-label study, 2 arms, 
N = 80, NCT04326920)
As of 28 May 2020, six companies had begun a clinical study treating patients with coronavirus disease 2019 (COVID-19) with monoclonal antibodies to granulocyte–
macrophage colony-stimulating factor (GM-CSF) or GM-CSF receptor (GM-CSFR). One company is also supporting investigator-initiated trials of recombinant 
human GM-CSF (rhuGM-CSF) in patients with COVID-19. CAR chimeric antigen receptor; CMML, chronic myelomonocytic leukaemia; CRS, cytokine release 
syndrome; GCA, giant cell arteritis; GvHD, graft-versus-host disease; HVs, healthy volunteers; MS, multiple sclerosis; NT, neurotoxicity; OA, osteoarthritis;  
OLE, open-label extension; PD, Parkinson disease; PsO, psoriasis; RA, rheumatoid arthritis; RCT, randomized controlled trial (double-blind unless otherwise stated);  
SpA, spondyloarthritis; ×3 or ×4, three or four of the indicated trials are ongoing or have been completed. aInformation obtained from ClinicalTrials.gov or company 
public announcements.
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levels of GM-CSF directly to the lungs may 
be required for a therapeutic effect55,56.
Across many preclinical models of 
viral and bacterial pneumonia, GM-CSF 
expression in the lung has been shown to 
serve a beneficial role by enhancing repair 
of injured lung tissue and by activating 
innate and adaptive immune responses 
to clear pathogens19,50,56–63. In this context, 
GM-CSF is thought to act mainly on alveolar 
macrophages and tissue-resident CD103+ 
dendritic cells, and there is even evidence 
that GM-CSF directly modulates alveolar 
epithelial cells19,50,64. Pretreatment with 
intranasally administered GM-CSF protected 
mice from lethal influenza-induced lung 
injury56,60, and lung-specific overexpression 
of GM-CSF after influenza viral infection 
in an inducible transgenic mouse model 
significantly increased survival61. Inhaled 
GM-CSF also protected against secondary 
bacterial infection in a postinfluenza 
pneumococcal pneumonia mouse model62. 
Conversely, GM-CSF-deficient mice showed 
no survival 48 hours after intratracheal 
inoculation with Gram-negative bacteria 
(compared with 100% survival in controls) 
due to impaired alveolar macrophage 
bactericidal function63. During infection 
resolution, GM-CSF was shown to mediate 
macrophage–epithelial cell crosstalk, 
stimulating alveolar epithelial cell 
proliferation and barrier repair64,65. In 
six patients with pneumonia-associated 
ARDS, compared with an external control 
group, increased oxygenation and lung 
compliance were observed following 
treatment with inhaled GM-CSF on a 
compassionate use basis; however, these 
results will need to be verified in controlled 
studies55. Currently, a randomized, 
open-label, investigator-initiated trial 
is ongoing to assess inhaled and/or 
intravenously administered sargramostim 
in patients with acute hypoxic respiratory 
failure due to COVID-19 (N = 80, 
NCT04326920)66. A randomized, 
double-blind, placebo-controlled study has 
also been initiated to assess intravenously 
administered sargramostim in 30 patients 
with respiratory failure due to COVID-19 
(NCT04400929)66 (Table 1). This strategy 
may prove useful for stabilizing alveolar 
macrophage and epithelial cell function, 
increasing SARS-CoV-2 clearance, 
protecting against secondary infection and 
contributing to lung repair mechanisms.
Risks associated with GM-CSF 
administration in COVID-19. Sargramostim 
is typically used clinically to expand bone 
marrow progenitor cells and promote 
myeloid reconstitution, for example, in cases 
of neutropenia following chemotherapy or 
autologous bone marrow transplantation. In 
apparent contradiction to the data presented 
in the previous subsection, the sargramostim 
FDA label cautions against treating patients 
with hypoxia because its administration has 
been shown to induce respiratory symptoms 
due to excessive granulocyte mobilization 
into the lungs from the circulation67. It 
was demonstrated in healthy volunteers 
that neutrophils primed ex vivo with 
GM-CSF are sequestered in the pulmonary 
vasculature, whereas little to no retention 
was observed with non-primed cells68. 
Considering that neutrophil accumulation 
in the lung is a hallmark of ARDS69, it is 
noteworthy that acute lung injury has been 
reported as a potential complication of 
sargramostim use in rare cases70. GM-CSF 
has been shown to boost neutrophil 
survival in ARDS, and thus inhibition of the 
GM-CSF pathway has been proposed as a 
potential ARDS therapeutic approach17,28,71, 
contrary to recommendations in many of the 
aforementioned reports.
Given the aforementioned literature, 
careful monitoring will be needed with 
sargramostim use in the COVID-19 setting, 
particularly as late stages of COVID-19 
are thought to be driven by host overactive 
immunity rather than high viral load43. 
GM-CSF administration can induce flu-like 
symptoms, leukocytosis and capillary leak 
syndrome67, therefore posing the potential 
risk of exacerbating the SARS-CoV-
2-induced hyperinflammatory response. 
BALF analyses of patients with COVID-19 
have shown that alveolar macrophages are 
depleted in patients with severe COVID-19 
(refs46), indicating perhaps that GM-CSF 
administration may be more beneficial 
in patients with earlier-stage COVID-19. 
Indeed, the COVID-19 trials assessing 
GM-CSF administration exclude patients 
with ferritin levels greater than 2,000 µg ml−1 
(consistent with ongoing HLH) and thus 
may treat patients before they progress to an 
overt hyperinflammatory phenotype.
Rationale for neutralizing GM-CSF in 
COVID-19. Anti-inflammatory therapies 
have attracted great interest in COVID-19, 
and an immunomodulatory agent that is 
able to prevent or reduce the disease-driving 
hyperactive immune response could be a 
beneficial therapy for late-stage COVID-19  
(ref.25). In COVID-19 and other 
coronavirus-mediated diseases, pathogenic 
myeloid cell overactivation is thought to be 
an important mediator of tissue damage, 
hypercoagulation and the cytokine storm44,72. 
BALF analyses from patients with mild  
or severe COVID-19 showed that patients 
with severe COVID-19 experienced 
significant lung infiltration by circulating 
inflammatory monocyte-derived 
macrophages46. Due to its role as a myeloid 
cell growth factor and pro-inflammatory 
cytokine, GM-CSF may be a key driver of the 
immunopathological sequelae of COVID-19.
Although virtually undetectable in the 
circulation of healthy individuals14, GM-CSF 
was recently noted as being upregulated 
in the serum of a subset of patients with 
COVID-19 (ref.73). It was reported that 
the percentages of GM-CSF-expressing 
CD4+ T cells, CD8+ T cells, natural killer 
cells and B cells were significantly higher 
in the blood of patients with COVID-19 
who were admitted to an intensive care 
unit (ICU) than in healthy controls1. This 
pan-cellular observation was not seen 
with IL-6 and TNF expression in the 
respective populations. Furthermore, a 
GM-CSF+IFNγ+CD4+ T cell signature, 
which is associated with GvHD31 and 
autoimmune arthritis26, encephalomyelitis74 
and diabetes75, was found in the peripheral 
blood of the patients in the ICU. These T cell 
responses were accompanied by a significant 
increase in the numbers of CD14+CD16+ 
inflammatory monocytes, and a high 
percentage of monocytes secreted GM-CSF 
and IL-6 (ref.1). The reported immunological 
changes appeared to be more pronounced 
in patients admitted to an ICU than in those 
who did not require ICU care and thus 
appear to correlate with clinical severity. 
Similarly, a study in patients with sepsis 
demonstrated that an increased percentage 
of circulating GM-CSF-producing TH cells 
is predictive of poor outcome and is 
correlated with IL-1 and IL-6 expression; 
these cells exhibited a memory phenotype 
and were reported to be mediators of 
dysfunctional neutrophil activity38. However, 
given the role of GM-CSF in pathogen 
clearance and lung repair, it is important 
to consider that GM-CSF levels may be 
elevated as a compensatory mechanism or 
as a background consequence of increased 
COVID-19 severity. Further studies are 
therefore needed to determine whether 
increased production of GM-CSF in patients 
with COVID-19 represents a physiological 
response to infection or a pathogenic driver 
of disease.
We, along with others1,72, suggest that 
in patients with COVID-19, dysregulated 
GM-CSF expression could induce 
overactivation of myeloid cells that 
secrete pro-inflammatory mediators and 
destructively infiltrate tissue, such as 
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the lungs and potentially even the heart 
and the nervous system. This suggestion 
is consistent with the disease-driving 
mechanism of action of GM-CSF proposed 
in many preclinical models with pathologies 
similar to that of late stages of COVID-19, 
including models of chimeric antigen 
receptor (CAR) T cell-related CRS and 
neurotoxicity76, GvHD-associated CRS31, 
septic shock77,78, neuroinflammatory 
disease21, inflammatory lung 
conditions71,79–85 and acute cardiovascular 
diseases (myocarditis86, myocardial 
infarction33 and vasculitis87). Therapeutic 
inhibition of GM-CSF has shown benefit 
(including survival advantages) in all of 
these preclinical models by decreasing the 
production of multiple pro-inflammatory 
cytokines/chemokines and reducing tissue 
infiltration by inflammatory immune 
cells2,3. Of note, a recent report described 
an outbreak of ‘Kawasaki-like’ disease 
in SARS-CoV-2-infected children88, and 
GM-CSF neutralization via mAb in a mouse 
model of Kawasaki disease led to significant 
reductions in disease incidence and 
severity89. With respect to the lung, systemic 
monoclonal anti-GM-CSF administration 
after intranasal lipopolysaccharide challenge 
in mice reduced the lung accumulation of 
myeloid cells in a dose-dependent manner79. 
A similar benefit was achieved with the 
use of GM-CSF neutralization to treat 
inflamed lungs in multiple other mouse 
studies80–83. A phase II trial of monoclonal 
anti-GM-CSF administration in patients 
with asthma demonstrated no benefit in 
the overall population but statistically 
significant improvement versus placebo 
on the primary outcome measure in 
prespecified subgroups32.
In mouse models of SARS-CoV infection, 
GM-CSF was proposed as a mediator of the 
lethal SARS-CoV-induced infiltration of 
inflammatory monocytes/macrophages into 
the lungs90. GM-CSF was upregulated before 
all other cytokines (IL-6, TNF and IFNβ) 
and chemokines (CCL2, CCL7 and CCL12) 
that were measured, indicating that GM-CSF 
might be involved in the initiation of this 
immunopathological process. In these 
studies, genetically modified mice (Ifnar−/− 
mice, which cannot respond to type I 
interferon) did not experience the early 
upregulation of GM-CSF and were protected 
from the cellular infiltration and death90. 
Experimental depletion of inflammatory 
monocytes and macrophages resulted 
in significantly reduced morbidity and 
mortality (100% survival out to ~2 weeks 
versus ~20–40% in controls) and increased 
numbers of virus-specific T cells in the 
lungs, demonstrating the therapeutic 
potential of downregulating inflammatory 
myeloid cells in coronavirus infections90.
Together, these data suggest that the 
use of mAbs to GM-CSF or GM-CSFR 
might be a promising therapeutic strategy 
for curbing the hyperactive host immune 
response observed in COVID-19. A 
number of large clinical trials in patients 
with COVID-19 are currently assessing 
similar immunomodulatory strategies. 
These include IL-6 targeting via sarilumab 
or tocilizumab, the latter of which is 
FDA-approved for CAR T cell-related 
CRS72, and IL-1 blockade with anakinra 
or canakinumab72,91. Recently, a data 
monitoring committee analysis of an 
ongoing phase II/III randomized controlled 
trial of sarilumab showed a large reduction 
in C-reactive protein levels and an increase 
versus placebo on ventilator-free survival 
in ‘critical’ patients with COVID-19 
(requiring high-flow oxygenation, 
mechanical ventilation or ICU care at 
study entry) (N = 44 receiving placebo, 
N = 88 receiving high-dose sarilumab 
therapy, no P values reported)92. The data 
monitoring committee recommended 
stopping the assessment of low-dose 
treatment, as well as discontinuing the 
enrolment of patients with “severe” disease 
(requiring supplemental oxygen without 
mechanical or high-flow oxygenation) 
and patients exhibiting multiorgan system 
dysfunction, demonstrating the importance 
of timing and dose strength for the 
use of immunomodulatory biologics in 
COVID-19 (ref.92). The careful assessment 
of the designs and results of these types of 
cytokine-targeting mAb clinical trial will 
be important for setting expectations and 
implementing amendments during the 
ongoing GM-CSF-targeted mAb clinical 
trials in patients with COVID-19.
Because GM-CSF can stimulate 
the expression of IL-1, IL-6, TNF and 
other pro-inflammatory cytokines and 
chemokines, a GM-CSF-targeting strategy 
might have broader effects than other 
immunomodulatory approaches when one is 
seeking to therapeutically dampen overactive 
immune responses. This hypothesis is 
supported by data from clinical trials in 
which GM-CSF-targeted therapy was shown 
to be efficacious in patients with rheumatoid 
arthritis who were unresponsive to 
TNF-targeted therapy93,94. In a head-to-head 
study comparing GM-CSF blockade with 
monoclonal anti-TNF therapy in patients 
with rheumatoid arthritis, GM-CSF 
blockade induced a sustained reduction in 
the levels of markers of inflammation, such 
as C-reactive protein and IL-6, whereas 
monoclonal anti-TNF therapy did not in 
the particular population under study40. 
Even given the benefits of tocilizumab in 
CRS, it has been speculated that patients 
can become refractory owing to early and 
sustained upregulation of GM-CSF76,95,96, 
and clinical trials are ongoing or planned 
to assess the benefit of GM-CSF-targeting 
mAbs in CAR T cell-related CRS and in CRS 
associated with GvHD4–6.
In summary, these data suggest that 
GM-CSF can have a master regulatory 
effect on cytokine expression and myeloid 
cell-mediated hyperinflammation, including 
in the lung. Many of the preclinical and 
clinical data from the GM-CSF-targeting 
mAb therapeutic class come from 
inflammatory disorders not caused by 
a viral pathogen, making extrapolation 
to COVID-19 difficult. However, as 
mentioned earlier, late stages of COVID-19 
appear to be driven not by active viral 
replication and cell lysis but instead by host 
immunopathology — particularly myeloid 
cell immunopathology — that is similar to 
many aspects of these disorders43,72. Thus, 
the putative pathogenic role of GM-CSF in 
immune overactivation across many studies 
provides a rationale for the initiation of the 
ongoing randomized controlled trials using 
GM-CSF-targeting mAbs for the treatment 
of patients with COVID-19 (Table 1).
Risks associated with GM-CSF inhibition 
in COVID-19. Given the homeostatic role 
of GM-CSF in the lung, blocking GM-CSF 
action in patients with COVID-19  
comes with the potential risks of 
compromising alveolar macrophage 
function and hindering pathogen clearance. 
As with any anti-inflammatory approach 
under investigation in COVID-19, close 
monitoring for evidence of viral exacerbation 
will be needed. Importantly, mAbs to 
GM-CSF and GM-CSFR have demonstrated 
a strong safety profile to date across more 
than 1,000 patients treated in multiple 
phase II trials2, including a long-term safety 
study where patients were receiving the 
therapy for a median of 2.5 years97. Although 
secondary infections could have been 
expected (as can be observed in patients 
receiving TNF- or IL-6-targeted therapy), 
no increase in tuberculosis and other 
serious infections has so far been noted2. 
While PAP is of theoretical concern, no 
patient has developed this disease in any 
monoclonal anti-GM-CSF or monoclonal 
anti-GM-CSFR trial to date. It has been 
hypothesized that primary PAP can develop 
only from dramatic and sustained GM-CSF 
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neutralization by polyclonal antibodies 
(for example, autoantibodies)98.
In the COVID-19 setting, therapeutic 
intervention will occur over a short time 
frame (likely 2 weeks or less), lessening 
the risk of lung toxicity. Furthermore, the 
timing of mAb administration may be 
very important. Although GM-CSF 
could be beneficial for maintaining 
alveolar macrophage function during the 
viral assault in the early disease phase, 
neutralizing GM-CSF may be able to reduce 
the primary pathology of the cytokine storm 
and myeloid cell-induced lung destruction 
in later disease stages.
mAbs to GM-CSF and GM-CSFR in 
development to treat COVID-19. A number 
of clinical trials of systemically administered 
mAbs to GM-CSF or GM-CSFR have been 
completed or are ongoing for inflammatory/
autoimmune conditions; recently, six 
companies initiated clinical studies assessing 
these mAbs for the treatment of COVID-19 
(Table 1). Encouraging data were obtained 
from an open-label cohort study of patients 
with COVID-19 treated with the GM-CSFR 
mAb mavrilimumab (N = 13), compared 
with a matched contemporaneous untreated 
control group (N = 26)6. Benefits in the 
mavrilimumab-treated group were reported 
across multiple clinically relevant end points, 
including time to hospital discharge and 
mortality; mavrilimumab was observed 
to be well tolerated in all patients, with no 
infusion reactions6. However, these findings 
need to be confirmed in larger studies that 
are placebo controlled.
As of 28 May 2020, six randomized, 
double-blind, placebo-controlled trials 
were ongoing for GM-CSF-targeting mAbs 
in COVID-19 (Table 1). The lenzilumab 
trial (N = 238, NCT04351152) excludes 
patients with ARDS, and the mavrilimumab 
trials (N = 60, NCT04399980; N = 50, 
NCT04397497) exclude patients receiving 
mechanical ventilation at the time of 
randomization. By contrast, the otilimab 
(N = 800, NCT04376684), gimsilumab 
(N = 270, NCT04351243), and TMJ2 
(N = 144, NCT04341116) trials allow 
inclusion of these patients. The differing 
target patient populations in these studies 
should indicate whether targeting GM-CSF 
may be effective at early and/or late stages 
of COVID-19. Of note, there is expected 
to be little difference between targeting the 
GM-CSF ligand versus the receptor because 
both strategies block the same interaction. 
Indeed, preclinical and clinical trial data in 
rheumatoid arthritis have shown similar 
benefits for these two approaches2.
Conclusion
We have provided the rationale and risks 
for both therapeutically administering and 
inhibiting GM-CSF in COVID-19. Given 
the pleiotropic roles of GM-CSF in lung 
health, host defence and inflammation, 
care should be taken with respect to dose, 
route and timing of administration for 
each therapeutic approach. GM-CSF 
administration in patients with COVID-19 
may improve lung function by strengthening 
the alveolar wall and enhancing viral 
clearance, and this approach may thus 
provide particular benefit in early stages 
of COVID-19. By contrast, GM-CSF or 
GM-CSFR blockade could be a beneficial 
treatment for the cytokine storm and 
inflammatory myeloid cell tissue infiltration 
associated with moderate-to-severe 
COVID-19. The GM-CSF blockade strategy 
may have broad immunomodulatory effects 
given that it could affect the secretion of 
multiple pro-inflammatory cytokines and 
chemokines by myeloid cells. In our view, 
the GM-CSF-based therapies are worthwhile 
investigational approaches during the 
urgent global search for effective COVID-19 
therapeutics.
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